Olaparib Addition to Maintenance Bevacizumab Therapy in Ovarian Carcinoma With BRCA-Like Genomic Aberrations
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.The BRCA-like genomic profile accurately predicts treatment response in high-grade ovarian cancer. Patients with BRCA-like tumors benefit significantly from olaparib plus bevacizumab maintenance therapy, improving progression-free survival (PFS).
Area Of Science
- Oncology
- Genomics
- Clinical Trials
Background
- Homologous recombination deficiency (HRD) testing is crucial for optimizing high-grade epithelial ovarian cancer treatment.
- Accurate biomarkers for HRD are continuously being sought to guide therapeutic decisions.
- Olaparib, a PARP inhibitor, shows efficacy in ovarian cancer, particularly in patients with BRCA mutations.
Purpose Of The Study
- To determine if progression-free survival (PFS) and overall survival (OS) differ in high-grade epithelial ovarian cancer patients treated with maintenance olaparib or placebo based on BRCA-like genomic profile.
- To investigate the interaction between BRCA-like status and olaparib treatment efficacy on survival outcomes.
Main Methods
- Secondary analysis of the PAOLA-1 randomized clinical trial involving patients with advanced high-grade ovarian cancer.
- Tumor homologous recombination deficiency was assessed using a BRCA-like copy number aberration profile classifier.
- Cox proportional hazards regression was used to analyze hazard ratios (HRs) and test for interactions between BRCA-like status and olaparib treatment on PFS and OS.
Main Results
- A total of 442 patients had BRCA-like classification performed. Patients with a BRCA-like tumor showed significantly longer PFS with olaparib plus bevacizumab compared to placebo (36.4 vs 18.6 months; HR, 0.49; P < .001).
- No significant PFS benefit was observed with olaparib in patients with non-BRCA-like tumors (17.6 vs 16.6 months; HR, 1.02; P = .93).
- A significant interaction between BRCA-like status and olaparib treatment was found (P = .004), with similar trends observed for OS.
Conclusions
- Patients with a BRCA-like tumor profile experienced significantly longer survival with olaparib plus bevacizumab maintenance therapy compared to placebo plus bevacizumab.
- The BRCA-like classifier demonstrates potential as a predictive biomarker for selecting patients who will benefit from olaparib plus bevacizumab maintenance treatment in advanced ovarian cancer.
- This finding supports the use of genomic profiling to personalize treatment strategies in high-grade epithelial ovarian cancer.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
Related Concept Videos
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Since the discovery of the two BER pathways, there has been a debate about how a cell chooses one pathway over the other and the factors determining this selection. Numerous in vitro experiments have pointed out multiple determinants for the sub-pathway selection. These are:
Lesion type: Depending on the type of base damage, a specific DNA glycosylase - mono or bifunctional, is recruited to the damaged site. While the sequential action of a monofunctional glycosylase favors long patch repair...
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
